Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells

Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.

Full text not available from this repository.
Item Type: Article
Status: Published
Official URL: https://doi.org/10.3390/ijms23031671
Journal or Publication Title: International Journal of Molecular Sciences
Volume: 23
Number: 3
Page Range: p. 1671
Date: 2022
Divisions: Gene and Stem Cell Therapy
Depositing User: General Admin
Identification Number: 10.3390/ijms23031671
ISSN: 1422-0067
Date Deposited: 17 Mar 2022 01:09

Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type, characterized by a dismal prognosis due to late diagnosis, frequent metastases, and limited therapeutic response to standard chemotherapy. Circulating tumor cells (CTCs) are a rare subset of tumor cells found in the blood of cancer patients. CTCs has the potential utility for screening, early and definitive diagnosis, prognostic and predictive assessment, and offers the potential for personalized management. However, a gold-standard CTC detection and enrichment method remains elusive, hindering comprehensive comparisons between studies. In this review, we summarize data regarding the utility of CTCs at different stages of PDAC from early to metastatic disease and discuss the molecular profiling and culture of CTCs. The characterization of CTCs brings us closer to defining the specific CTC subpopulation responsible for metastasis with the potential to uncover new therapies and more effective management options for PDAC.

Yeo, Dannel
Bastian, Althea
Strauss, Heidi
Saxena, Payal
Grimison, Peter
Rasko, John E. J.
Last Modified: 17 Mar 2022 01:09
URI: https://eprints.centenary.org.au/id/eprint/1201

Actions (login required)

View Item View Item